“…Y IL-8 P, danazol, dienogest (63) In vitro, EcSC Y IL-8 IKK-2 inhibitor (64) In vitro, EcEC line Y IL-8, IL-6, MCP-1, GM-CSF, ICAM-1 and MMP-9 Y cell invasion Pioglitazone (88) In vitro, EcSC Y IL-8 and cell proliferation IL-10 (159) In vitro, EcSC Y IL-6 NF-kB decoy ODNs (68) In vitro, EcSC Y RANTES Y monocyte chemotactic activity BAY- 11-7085 (33, 87) In vitro, EcSC Y Bcl-2 and Bcl-XLn [ caspase-3, -9, and -8 activation In vivo, nude mouse a Y Ec lesion development Y cell proliferation and [ apoptosis Y ICAM-1 PDTC and bortezomib (138) In vivo, rat c Y Ec lesion development Y cell proliferation and angiogenesis CAPE (162) In vivo, rat c Y Ec lesion development Y oxidative stress Eicosapentanoic acid (163) In vivo, rat c Y inflammation Y PGES, MMP-13 and NF-kB Glycine (164) In vivo, hamster d No effect hCG (165,166) In vitro, EcSC Y IL-1b and TNF-a In vivo, human Y symptoms ERb agonist (155) In vitro, peritoneal Mo Y iNOS Note: Unless otherwise specified, in vitro studies were performed on human cells. Bcl ¼ B-cell lymphoma/leukemia; CAPE ¼ caffeic acid phenethyl ester; COX ¼ cyclooxygenase; EcEC ¼ endometriotic epithelial cells; EcSC ¼ endometriotic stromal cells; EEC ¼ endometrial epithelial cells; ER ¼ estrogen receptor; ESC ¼ endometrial stromal cells; GM-CSF ¼ granulocyte macrophage-colony-stimulating factor; GnRH-a, gonadotropin-releasing hormone agonist; hCG, human chorionic gonadotropin; ICAM, intercellular adhesion molecule; IKK ¼ IkB kinase; IL ¼ interleukin; iNOS ¼ inducible nitric oxide synthase; LIF ¼ leukemia inhibitory factor; MIF ¼ macrophage-migration inhibitory factor; MMP ¼ matrix metalloproteinase; Mo ¼ macrophages; ODNs ¼ decoy oligonucleotides; P ¼ progesterone; PDTC ¼ pyrrolidine dithiocarbamate; PGES ¼ prostaglandin E synthase, PTGS ¼ prostaglandinendoperoxide synthase; RANTES ¼ regulated upon activation, normal T-cell expressed and secreted; TNF-a ¼ tumor necrosis factor-a; TPCK ¼ N-tosyll-phenylalanine chloromethyl ketone.…”